🔎 Trials Near Me

홈 › 급성 골수성 백혈병 › 애리조나

애리조나의 급성 골수성 백혈병 임상 시험

급성 골수성 백혈병 관련 연구 23개가 애리조나 내 여러 지역에서 참여자를 모집하고 있습니다.

애리조나의 도시

공식 연구 텍스트(영어)

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06317649

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Banner MD Anderson Cancer Center, Gilbert
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07007312

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Mayo Clinic Hospital in Arizona, Phoenix
  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05554406

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Kingman Regional Medical Center, Kingman
  • Cancer Center at Saint Joseph's, Phoenix
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Cancer Treatment Center of America Phoenix, Goodyear
  • The University of Arizona Cancer Center, Tucson
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Mayo Clinic Hospital in Arizona, Phoenix
  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT05564390

Prophylactic DLI-X for Leukemia Relapse After HCT

  • The University of Arizona Cancer Center, Tucson
피험자 모집 중1상
65세 이하 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT07254793

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  • Mayo Clinic Hospital - Phoenix, Phoenix
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05143996

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05554393

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06672146

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy

  • Mayo Clinic in Arizona, Scottsdale
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06279572

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Goodyear
피험자 모집 중3상
12세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07211958

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Banner Children's at Desert, Mesa
  • Phoenix Childrens Hospital, Phoenix
  • Banner University Medical Center - Tucson, Tucson
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • Mayo Clinic Arizona, Phoenix
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04996875

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • City of Hope - Phoenix, Goodyear
  • Mayo Clinic, Phoenix
  • Honor Health, Scottsdale
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT04588922

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Banner Children's at Desert, Mesa
  • Phoenix Childrens Hospital, Phoenix
  • Banner University Medical Center - Tucson, Tucson
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Banner MD Anderson Cancer Center, Gilbert
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Banner MD Anderson Cancer Center, Gilbert
  • Phoenix Children's Hospital, Phoenix
  • University of Arizona Medical Center - Tucson, Tucson
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT01351545

Caris Chromoseq Data Collection

  • Caris Life Sciences, Phoenix
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT07680868

Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

  • Phoenix Children's Hospital, Phoenix
피험자 모집 중1상
21세 이하 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT05101551

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

  • Mayo Clinic Arizona, Phoenix
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT05732103

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Mayo Clinic - Phoenix, Phoenix
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.